Skip to main content
GetPepWell
Weight Management

Semaglutide

Physician-supervised compounded GLP-1 therapy for chronic weight management.

Compounded preparation

From$299/mo

Get startedSchedule consultation
Semaglutide

How it works

Semaglutide is a 94% structural analog of human GLP-1 with key amino acid substitutions at positions 8 and 34 that confer resistance to DPP-4 enzymatic degradation. It binds to and activates GLP-1 receptors in the hypothalamic arcuate nucleus, stimulating POMC/CART neurons (which promote satiety) while inhibiting NPY/AgRP neurons (which drive hunger). In the gastrointestinal tract, it slows gastric emptying by reducing vagal-mediated motility, prolonging the feeling of fullness after meals. It also acts on pancreatic beta cells to enhance glucose-dependent insulin secretion and suppress glucagon release from alpha cells. The albumin-binding fatty acid side chain extends the half-life to approximately 7 days, enabling once-weekly dosing.

Key benefits

  • GLP-1 receptor agonists have been studied for weight management
  • Reduced appetite and food cravings through central-nervous-system signaling
  • Improved glycemic control with lower fasting blood glucose and HbA1c (studied in the finished product)
  • Cardiovascular risk reduction studied in the finished product (SELECT trial)
  • Improvements in blood pressure and lipid profile reported in finished-product studies
  • Once-weekly dosing schedule supports adherence
  • Reduced visceral (abdominal) fat reported in finished-product studies
  • Potential improvements in non-alcoholic fatty-liver-disease markers (finished-product data)

Clinical research

The clinical-trial evidence for semaglutide weight management was developed for the branded finished products (Ozempic® and Wegovy®, registered trademarks of Novo Nordisk), not for any compounded preparation. The STEP trial program studied finished-product semaglutide across multiple populations (STEP 1 in adults with obesity; STEP 2 in patients with type 2 diabetes; STEP 3 with intensive behavioral therapy; STEP 4 on discontinuation; STEP 5 extended-duration data). The SELECT cardiovascular outcomes trial studied the finished product in overweight or obese adults without diabetes. The compounded preparation dispensed by GetPepWell has not undergone equivalent finished-product efficacy or safety testing; finished-product trial results should be read as evidence about the molecule and its mechanism, not as a guarantee of identical outcomes from the compounded preparation. Your physician will discuss realistic expectations at consultation.

Side effects

  • Nausea (most common, typically decreases over 4-8 weeks)
  • Diarrhea or constipation
  • Vomiting, particularly during dose escalation
  • Abdominal pain or bloating
  • Headache
  • Fatigue
  • Injection site reactions (redness, swelling)
  • Decreased appetite (therapeutic effect but can be pronounced)

Contra-indications

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Known hypersensitivity to semaglutide or any excipients
  • History of pancreatitis
  • Pregnancy or planning to become pregnant (discontinue at least 2 months before conception)
  • Breastfeeding
  • Severe gastroparesis or gastrointestinal disease
  • End-stage renal disease (eGFR below 15 mL/min)

Drug interactions

  • Insulin or sulfonylureas - increased risk of hypoglycemia; dose adjustment may be needed
  • Oral contraceptives - delayed gastric emptying may reduce absorption; consider non-oral methods
  • Warfarin - monitor INR more frequently during initiation and dose changes
  • Levothyroxine - absorption may be affected; take thyroid medication on an empty stomach
  • Oral medications with narrow therapeutic index - monitor levels due to altered absorption timing

Storage info

Store unused vials refrigerated at 36-46 degrees F (2-8 degrees C). Do not freeze. After first use, the vial may be kept at room temperature (up to 86 degrees F / 30 degrees C) or refrigerated for up to 28 days. Protect from direct sunlight and heat. Discard 28 days after first use regardless of remaining volume. Do not use if the solution appears cloudy, discolored, or contains particles.

Common questions

Semaglutide FAQ

Find answers to the most common questions about this treatment.

Interested in Semaglutide?

Schedule a consultation with a licensed physician to see if this treatment is right for you.

Sign up nowBrowse all products